Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CASP3 | P42574 | 4/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9234192 | 0.89 | KMT2A (0.43) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL4413972 | 0.82 | KMT2A (0.43) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL27960451 | 0.82 | KMT2A (0.47) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL20184843 | 0.82 | KMT2A (0.47) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL30341743 | 0.81 | KMT2A (0.49) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL15119354 | 0.80 | KMT2A (0.60) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL15058849 | 0.80 | KMT2A (0.55) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL19517972 | 0.79 | KMT2A (0.45) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL23296943 | 0.79 | KMT2A (0.44) | KMT2ACASP3EPHX2FABP5FABP7 | |
| SCHEMBL28857903 | 0.79 | KMT2A (0.50) | KMT2ACASP3EPHX2FABP5FABP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2019-07-11 | — | — | US | disclosed |
| EP-3209334-A2 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Igenica Biotherapeutics, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190209704-A1 | NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | CYTH3, CD47, FCGRT | KMT2A 2145/4885CASP3 572/4885EPHX2 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.